Randomized Pilot Trial of Bariatric Surgery Versus Intensive Medical Weight Management on Diabetes Remission in Type 2 Diabetic Patients Who Do NOT Meet NIH Criteria for Surgery and the Role of Soluble RAGE as a Novel Biomarker of Success
Authors:
- Manish ParikhMPManish Parikh
- Mimi ChungMCMimi Chung
- Sheetal ShethSSSheetal Sheth
- Michelle McMackenMMMichelle McMacken
- John K. SaundersJSJohn K. Saunders
- Aku Ude-WelcomeAUAku Ude-Welcome
- H. Leon PachterHPH. Leon Pachter
- 1 October 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 260 (4) , 617-624
Abstract
Objective: To compare bariatric surgery versus intensive medical weight management (MWM) in patients with type 2 diabetes mellitus (T2DM) who do not meet current National Institutes of Health criteria for bariatric surgery and to assess whether the soluble form of receptor for advanced glycation end products (sRAGE) is a biomarker to identify patients most likely to benefit from surgery. Background: There are few studies comparing surgery to MWM for patients with T2DM and BMI less than 35. Methods: Fifty-seven patients with T2DM and BMI 30 to 35, who otherwise met the criteria for bariatric surgery were randomized to MWM versus surgery (bypass, sleeve or band, based on patient preference). The primary outcomes assessed at 6 months were change in homeostatic model of insulin resistance (HOMA-IR) and diabetes remission. Secondary outcomes included changes in HbA1c, weight, and sRAGE. Results: The surgery group had improved HOMA-IR (−4.6 vs +1.6; P = 0.0004) and higher diabetes remission (65% vs 0%, P < 0.0001) than the MWM group at 6 months. Compared to MWM, the surgery group had lower HbA1c (6.2 vs 7.8, P = 0.002), lower fasting glucose (99.5 vs 157; P = 0.0068), and fewer T2DM medication requirements (20% vs 88%; P < 0.0001) at 6 months. The surgery group lost more weight (7. vs 1.0 BMI decrease, P < 0.0001). Higher baseline sRAGE was associated with better weight loss outcomes (r = −0.641; P = 0.046). There were no mortalities. Conclusions: Surgery was very effective short-term in patients with T2DM and BMI 30 to 35. Baseline sRAGE may predict patients most likely to benefit from surgery. These findings need to be confirmed with larger studies. ClinicalTrials.gov ID: NCT01423877Keywords
This publication has 26 references indexed in Scilit:
- Surgical Strategies That May Decrease Leak After Laparoscopic Sleeve GastrectomyAnnals of Surgery, 2013
- The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesityInternational Journal of Obesity, 2012
- Metabolic surgery for type 2 diabetesNature Medicine, 2012
- Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with DiabetesNew England Journal of Medicine, 2012
- Bariatric Surgery versus Conventional Medical Therapy for Type 2 DiabetesNew England Journal of Medicine, 2012
- Does a preoperative medically supervised weight loss program improve bariatric surgery outcomes? A pilot randomized studySurgical Endoscopy, 2011
- Gastric Bypass vs Sleeve Gastrectomy for Type 2 Diabetes MellitusArchives of Surgery, 2011
- Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic AdultsNew England Journal of Medicine, 2010
- RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mountsJournal of Leukocyte Biology, 2009
- Randomized Trial of Lifestyle Modification and Pharmacotherapy for ObesityNew England Journal of Medicine, 2005